Text Size

Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome

This study has been completed.
Sponsor:
Information provided by:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT00440882
First received: February 26, 2007
Last updated: October 8, 2008
Last verified: October 2008
History of Changes
  Purpose

Transforming Growth Factor-b1 (TGF-b1) is involved in the development of acute lung injury and in the fibroproliferation during acute respiratory distress syndrome (ARDS). Procollagen III Peptide (PIIINP) is a validated marker of fibroproliferation. PIIINP is associated with death in ARDS patients. The simultaneous changes of TGF-b1 and PIIINP were never studied in patients with ARDS. The relationships between TGF-b1 and the outcome of ARDS are unknown.

The aim of the study is to analyse the changes of TGF-b1 and PIIINP during ARDS and to show the relationships between TGF-b1 - PIIINP and the outcomes of ARDS.


Condition
Acute Respiratory Distress Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Changes of Transforming Growth Factor b1 and Procollagen III in Patients With Acute Respiratory Distress Syndrome

Further study details as provided by Assistance Publique Hopitaux De Marseille:

Estimated Enrollment: 80
Study Start Date: September 2004
Detailed Description:

Primary outcome: To analyse the changes of Transforming Growth Factor b1 and Procollagen III during the acute respiratory distress syndrome.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients whom suffered ARDS with a PaO2/FIO2 < 200 mmHg at a positive end-expiratory pressure (PEEP) ³ 5 cm H2O and for which ARDS criteria from less than 24 hours

Criteria

Inclusion Criteria:

  • ARDS with a PaO2/FIO2 < 200 mmHg at a positive end-expiratory pressure (PEEP) ³ 5 cm H2O
  • ARDS criteria from less than 24 hours
  • Informed consent

Exclusion Criteria:

  • Pregnancy
  • Chronic interstitial or fibrosis lung diseases
  • Hepatic chronic disease
  • Neutropenia £1 G/l
  • Corticosteroid (more than 200 mg/day of hydrocortisone or equivalent, less than 2 weeks before inclusion)
  • Immunosuppressive therapy within the last 30 days
  • Participation in any investigational drug or devices study within 30 days prior study entry
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00440882

Locations
France
Hopital Sainte Marguerite
Marseille, France, 13009
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Investigators
Principal Investigator: Jean-Marie FOREL, MD AP-HM
  More Information

No publications provided

Responsible Party: Dr FOREL JM, Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT00440882     History of Changes
Other Study ID Numbers: 2004/16
Study First Received: February 26, 2007
Last Updated: October 8, 2008
Health Authority: France: Ministry of Health

Additional relevant MeSH terms:
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Acute Lung Injury
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
 Infant, Newborn, Diseases
Lung Injury
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013